Treatment Hotspots and Controversies in Papillary Thyroid Microcarcinoma
The Oncologist · 10.11.2026
DOI: 10.1093/oncolo/oyag216 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 10.11.2026. Verfasst von Lixia Yu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hos…. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The significant global rise in the detection rate of papillary thyroid microcarcinoma (PTMC) has sparked intense debates concerning overdiagnosis and overtreatment. Consequently, therapeutic strategies are shifting from radical surgery toward risk-stratified management, including active surveillance (AS) and minimally invasive techniques (MIT). Core controversies focus on the necessity of surgical intervention, the extent of prophylactic central neck dissection, and selection criteria for MIT versus conventional surgery.
Methods
This review systematically evaluates the comparative evidence on AS, thermal ablation (TA), and surgical treatment for PTMC, highlighting divergent Eastern and Western management philosophies to provide an optimized framework for clinical decision-making.
Results
Although AS demonstrates favorable survival benefits and health economic advantages for patients with PTMC, unresolved clinical risks persist. Notably, Chinese guidelines adopt stricter standards compared to the international 10 mm threshold. Among MIT, TA exhibits well-established short-term efficacy; however, recent expert consensus emphasizes a strict therapeutic hierarchy to prevent misuse, given the paucity of long-term recurrence data.
Conclusion
An individualized framework based on risk stratification is essential for PTMC management, balancing oncological safety and quality of life.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology and Metabology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong First Medical University, Shandong Key Laboratory of R…
- School of Clinical Medicine, Shandong Second Medical University, Weifang, China.
- School of Clinical Medicine, Jining Medical University, Jining, China.
- Department of Gerontology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital.
Zitieren
APA
Yu, L., Liu, F., Wang, F., Yuan, S., Zhao, X., Gu, S., Guo, R., Zhao, J., & Zhang, W. (2026). Treatment Hotspots and Controversies in Papillary Thyroid Microcarcinoma. The Oncologist. https://doi.org/10.1093/oncolo/oyag216
Vancouver
Yu L, Liu F, Wang F, Yuan S, Zhao X, Gu S, et al. Treatment Hotspots and Controversies in Papillary Thyroid Microcarcinoma. The Oncologist. 2026. doi:10.1093/oncolo/oyag216
BibTeX
@article{Yu2026,
author = {Yu, Lixia and Liu, Fan and Wang, Fei and Yuan, Saiya and Zhao, Xiaolu and Gu, Shuo and Guo, Rui and Zhao, Junyu and Zhang, Wei},
title = {Treatment Hotspots and Controversies in Papillary Thyroid Microcarcinoma},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag216}
}
EUVIMED